Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression

被引:35
作者
Mosyagin, Igor [1 ]
Runge, Uwe [2 ]
Schroeder, Henry W. [3 ]
Dazert, Eike [4 ]
Vogelgesang, Silke [4 ]
Siegmund, Werner [5 ]
Warzok, Rolf W. [4 ]
Cascorbi, Ingolf [1 ]
机构
[1] Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24105 Kiel, Germany
[2] Ernst Moritz Arndt Univ Greifswald, Dept Neurol, Greifswald, Germany
[3] Ernst Moritz Arndt Univ Greifswald, Dept Neurosurg, Greifswald, Germany
[4] Ernst Moritz Arndt Univ Greifswald, Dept Neuropathol, Greifswald, Germany
[5] Ernst Moritz Arndt Univ Greifswald, Dept Clin Pharmacol, Greifswald, Germany
关键词
P-glycoprotein; MDR1; blood-brain barrier; pharmacotherapy resistance;
D O I
10.1111/j.1528-1167.2008.01661.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: There is evidence from studies in rodents that P-glycoprotein (P-gp) overexpression is implicated in the causation of refractory epilepsy. Genetic variants in the human ABCB1 (MDR1) gene were shown to affect the expression levels of the transporter in various tissues and to be associated with refractory epilepsy. However, the effect of the genetic variants on the P-gp level in epileptogenic brain tissue is poorly investigated. In the present study, we examined the impact of putatively functional polymorphisms 3435C>T and 2677G>T in the ABCB1 gene on the ABCB1 mRNA expression and P-gp content in human brain tissue from epileptogenic foci of the patients with refractory epilepsy. Methods: Fresh brain tissue specimens were obtained from therapy-refractory epilepsy patients during neurosurgery of the epileptogenic focus. We determined the ABCB1 mRNA expression in 23 samples using S' exonuclease-based real-time polymerase chain reaction (PCR) as well as the P-gp content in 32 samples determined by immunohistochemistry, genotyping was performed by PCR/restriction fragment length polymorphism (RFLP). Results: There was lack of association of 3435C>T and 2677G>T as well as diplotype configurations on ABCB1 mRNA expression and P-gp content in epileptogenic brain tissues. Conclusions: We cannot exclude an association of ABCB1 variants on P-gp function, but our results suggest that brain ABCB1 mRNA and protein expression is not substantially influenced by major ABCB1 genetic variants thus explaining in part results from case-control studies obtaining lack of association of ABCB1 polymorphisms to the risk of refractory epilepsy.
引用
收藏
页码:1555 / 1561
页数:7
相关论文
共 42 条
[1]   Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors [J].
Aronica, E ;
Gorter, JA ;
Jansen, GH ;
Van Veelen, CWM ;
Van Rijen, PC ;
Leenstra, S ;
Ramkema, M ;
Scheffer, GL ;
Scheper, RJ ;
Troost, D .
NEUROSCIENCE, 2003, 118 (02) :417-429
[2]   Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling [J].
Bauer, Bjoern ;
Hartz, Anika M. S. ;
Pekcec, Anton ;
Toellner, Kathrin ;
Miller, David S. ;
Potschka, Heidrun .
MOLECULAR PHARMACOLOGY, 2008, 73 (05) :1444-1453
[3]   Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [J].
Cascorbi, I ;
Gerloff, T ;
Johne, A ;
Meisel, C ;
Hoffmeyer, S ;
Schwab, M ;
Schaeffeler, E ;
Eichelbaum, M ;
Brinkmann, U ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :169-174
[4]   Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs [J].
Cascorbi, Ingolf .
PHARMACOLOGY & THERAPEUTICS, 2006, 112 (02) :457-473
[5]   Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy [J].
Dombrowski, SM ;
Desai, SY ;
Marroni, M ;
Cucullo, L ;
Goodrich, K ;
Bingaman, W ;
Mayberg, MR ;
Bengez, L ;
Janigro, D .
EPILEPSIA, 2001, 42 (12) :1501-1506
[6]   Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].
Fellay, J ;
Marzolini, C ;
Meaden, ER ;
Back, DJ ;
Buclin, T ;
Chave, JP ;
Decosterd, LA ;
Furrer, H ;
Opravil, M ;
Pantaleo, G ;
Retelska, D ;
Ruiz, L ;
Schinkel, AH ;
Vernazza, P ;
Eap, CB ;
Telenti, A .
LANCET, 2002, 359 (9300) :30-36
[7]   Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans [J].
Giessmann, T ;
May, K ;
Modess, C ;
Wegner, D ;
Hecker, U ;
Zschiesche, M ;
Dazert, P ;
Grube, M ;
Schroeder, E ;
Warzok, R ;
Cascorbi, I ;
Kroemer, HK ;
Siegmund, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (03) :192-200
[8]   Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1) [J].
Hitzl, M ;
Schaeffeler, E ;
Hocher, B ;
Slowinski, T ;
Halle, H ;
Eichelbaum, M ;
Kaufmann, P ;
Fritz, P ;
Fromm, MF ;
Schwab, M .
PHARMACOGENETICS, 2004, 14 (05) :309-318
[9]   The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells [J].
Hitzl, M ;
Drescher, S ;
van der Kuip, H ;
Schäffeler, E ;
Fischer, J ;
Schwab, M ;
Eichelbaum, M ;
Fromm, MF .
PHARMACOGENETICS, 2001, 11 (04) :293-298
[10]   Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].
Hoffmeyer, S ;
Burk, O ;
von Richter, O ;
Arnold, HP ;
Brockmöller, J ;
Johne, A ;
Cascorbi, I ;
Gerloff, T ;
Roots, I ;
Eichelbaum, M ;
Brinkmann, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3473-3478